AIM
RXRX icon

Arcadia Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Arcadia Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23K Hold
400
– – ﹤0.01% 246
2025
Q4 		$1.64K Hold
400
– – ﹤0.01% 244
2025
Q3 		$1.95K Buy
+400
New +$2.1K ﹤0.01% 242

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arcadia Investment Management's RXRX Position: Q1 2026 in Review

Arcadia Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 400 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #246.

Arcadia Investment Management first reported a position in RXRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.95K in Q3 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Arcadia Investment Management held 400 shares of Recursion Pharmaceuticals worth $1.23K as of Q1 2026.
  • Arcadia Investment Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Arcadia Investment Management's portfolio in Q1 2026, its #246 holding.
  • Arcadia Investment Management first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Arcadia Investment Management's Recursion Pharmaceuticals position peaked at $1.95K in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Arcadia Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.